Stay updated on Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial

Sign up to get notified when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Page revision updated from v3.3.3 to v3.3.4; this is an administrative update with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.0%
    Check dated 2026-01-16T05:00:32.000Z thumbnail image
  2. Check
    14 days ago
    No Change Detected
  3. Check
    22 days ago
    Change Detected
    Summary
    Added a new 2025 Blood Advances publication on risk stratification of low-dose cytarabine and venetoclax in AML ineligible for intensive chemotherapy; updated author designation for the related Blood Advances citation.
    Difference
    0.0%
    Check dated 2026-01-02T00:54:00.000Z thumbnail image
  4. Check
    29 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    Locations section now includes numerous new study sites across multiple countries and regions (e.g., Florida, Kentucky, Brussels, Tokyo, Buenos Aires, etc.), with several prior sites removed, altering where participants can enroll.
    Difference
    2%
    Check dated 2025-12-18T20:51:57.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Added a 2025 Blood Advances publication entry related to risk stratification of low-dose cytarabine with venetoclax. Updated the page revision to v3.3.2; the older PubMed publication note (v3.2.0) was removed.
    Difference
    0.1%
    Check dated 2025-11-27T03:00:50.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The government funding operating-status notice has been removed from the page, eliminating a site-wide alert about potential delays and updates. The study details (title, interventions, endpoints, and locations) remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-11-19T22:12:47.000Z thumbnail image
  8. Check
    86 days ago
    Change Detected
    Summary
    The new screenshot shows only administrative metadata updates (e.g., last update timestamp); core study content remains unchanged—To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.2%
    Check dated 2025-10-29T10:09:18.000Z thumbnail image

Stay in the know with updates to Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Venetoclax Combo vs Low Dose Cytarabine in AML Clinical Trial page.